Cue Biopharma, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Cue Biopharma develops biologic drugs designed to selectively modulate T cells within the body to treat cancer and autoimmune diseases, using its Immuno-STAT platform to engage specific T-cell subsets without broadly suppressing the immune system.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Ray SumitaChief Legal Compliance Officer | Sell | $52K | 1,844at $28.05 | Oct 12, 2026 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | Sell | $32K | 1,144at $28.05 | Oct 12, 2026 |
| Lin Shao-LeeChief Executive Officer | Sell | $30K | 1,087at $28.05 | Oct 12, 2026 |
| Lin Shao-LeeChief Executive Officer | Sell | $275K | 10,000at $27.50 | Oct 12, 2026 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | Sell | $45K | 1,519at $29.37 | Aug 13, 2026 |
| Ray SumitaChief Legal Compliance Officer | Sell | $196K | 6,442at $30.35 | Aug 13, 2026 |
| Ray SumitaChief Legal Compliance Officer | Sell | $70K | 2,383at $29.37 | Aug 13, 2026 |
| Ray SumitaChief Legal Compliance Officer | Sell | $125 | 4at $31.13 | Aug 13, 2026 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | Sell | $125K | 4,106at $30.35 | Aug 13, 2026 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | Sell | $93 | 3at $31.13 | Aug 13, 2026 |
| Lin Shao-LeeChief Executive Officer | Sell | $308K | 10,460at $29.48 | Aug 13, 2026 |
| Lin Shao-LeeChief Executive Officer | Sell | $67K | 2,375at $28.11 | Aug 13, 2026 |
| Lin Shao-LeeChief Executive Officer | Sell | $924K | 34,225at $26.99 | Aug 12, 2026 |
| Lin Shao-LeeChief Executive Officer | Sell | $147K | 5,423at $27.19 | Aug 13, 2026 |
| Lin Shao-LeeChief Executive Officer | Sell | $160K | 5,775at $27.75 | Aug 12, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable CUE activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.